×
About 933 results

ALLMedicine™ Eye Disorders Center

Research & Reviews  204 results

Sleep duration and the risk of major eye disorders: a systematic review and meta-analysis.
https://doi.org/10.1038/s41433-023-02403-4
Eye (London, England); Zhou M, Li DL et. al.

Jan 23rd, 2023 - To assess the relationship between sleep duration and the risk of major eye disorders including myopia, glaucoma, cataract, age-related macular degeneration (AMD), and diabetic retinopathy (DR). Databases including PubMed, Embase, Web of Science, ...

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04137120

Jan 17th, 2023 - The primary objective is to assess the safety of intravitreal aflibercept injections in patients with wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), macular edema secondary to...

Secreted protease ADAMTS18 in development and disease.
https://doi.org/10.1016/j.gene.2023.147169
Gene Nie J, Zhang W

Jan 13th, 2023 - ADAMTS18 was identified in 2002 as a member of the ADAMTS family of 19 secreted Zinc-dependent metalloproteinases. Prior to 2016, ADAMTS18 was known as a candidate gene associated with a wide range of pathologies, particularly various malignancies...

Myopic macular diseases: A review.
https://doi.org/10.1111/ceo.14200
Clinical & Experimental Ophthalmology; Ng DSC, Chan LKY et. al.

Jan 4th, 2023 - Recent evidence has demonstrated that the global public health burden of myopia is rising rapidly. Highly myopic eyes are associated with increased frequency of eye disorders that can lead to irreversible visual impairment. With recent technologic...

Smoking, dietary factors and major age-related eye disorders: an umbrella review of sys...
https://doi.org/10.1136/bjo-2022-322325
The British Journal of Ophthalmology; Kai JY, Zhou M et. al.

Dec 29th, 2022 - There is accumulating evidence of the associations between age-related eye diseases (AREDs) and smoking or dietary factors. We aimed to provide an umbrella review of the published literature pertaining to smoking or dietary intake as risk factors ...

see more →

Drugs  90 results see all →

Clinicaltrials.gov  10 results

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04137120

Jan 17th, 2023 - The primary objective is to assess the safety of intravitreal aflibercept injections in patients with wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), macular edema secondary to...

Natural History, Pathogenesis, and Outcome of Ocular Disorders
https://clinicaltrials.gov/ct2/show/NCT02821767

Dec 29th, 2022 - The National Eye Institute (NEI) is conducting a study to evaluate and provide standard treatment to participants with various diagnosed and undiagnosed ocular conditions. Objective: The primary objective of this protocol is to provide short term ...

Feasibility of Estimating the Prevalence of Malnutrition, Frailty and Sarcopenia in Older People in UK Biobank, Cross-sectional Study: A Study Protocol
https://clinicaltrials.gov/ct2/show/NCT04655456

Apr 30th, 2021 - The UK Biobank is a population-based study of a large prospective longitudinal cohort with information on 500,000 people, who were aged 40-69 when recruited in 2006-2010 from England, Scotland and Wales. The database includes demographic data, onl...

Evaluation and Treatment of People With Eye Diseases
https://clinicaltrials.gov/ct2/show/NCT00708955

Dec 16th, 2019 - The National Eye Institute (NEI) is conducting a study to evaluate and provide standard treatment to participants with various diagnosed and undiagnosed ocular conditions. Objectives: The primary objective of this protocol is to provide a reservoi...

Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina
https://clinicaltrials.gov/ct2/show/NCT01387165

Jun 8th, 2017 - The DEAL (Diabetes En America Latina) study was a multicenter, cross-sectional, epidemiological, questionnaire based study carried out between October 2004 and October 2005 in 9 Latin American countries. General practitioners (GP) from private set...

see more →

News  56 results

Pooled Safety Data Analysis of Tralokinumab Reported
https://www.medscape.com/viewarticle/985050

Dec 5th, 2022 - The most comprehensive safety analysis of tralokinumab to date shows nothing unexpected in patients with atopic dermatitis (AD) treated for up to a year, according to a review published in the British Journal of Dermatology. Dr Eric Simpson These ...

Encorafenib/Binimetinib Delivers Prolonged Survival in BRAF V600–Mutant Melanoma
https://www.onclive.com/view/encorafenib-binimetinib-delivers-prolonged-survival-in-braf-v600-mutant-melanoma

Oct 21st, 2022 - The combination of encorafenib (Braftovi) and binimetinib (Mektovi) led to sustained improvements in progression-free survival (PFS) and overall survival (OS), without new safety signals in patients with BRAF V600–mutant melanoma, according to 5-y...

How Can the US Improve Access to Eyeglasses?
https://www.medscape.com/viewarticle/974468

May 23rd, 2022 - Many Americans do not have access to a simple but life-changing device: eyeglasses. In a 2017 survey, nearly 1 in 10 Americans who reported needing glasses said they could not afford them. More than 2 million children in the United States also do ...

Study Confirms Link Between Dementia Risk and Eye Disorders
https://www.medscape.com/viewarticle/960267

Oct 6th, 2021 - NEW YORK (Reuters Health) - A heightened risk of all-cause dementia was found to be associated with age-related macular degeneration (AMD), cataract and diabetes-related eye disease (DRED), but not glaucoma, according to data from the UK Biobank. ...

Infigratinib Approved in Canada for FGFR2+ Cholangiocarcinoma
https://www.onclive.com/view/infigratinib-approved-in-canada-for-fgfr2-cholangiocarcinoma

Sep 29th, 2021 - Health Canada has approved infigratinib (Truseltiq) for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 fusion or other rearrangement.1 The FGFR inhibitor...

see more →

Patient Education  13 results see all →